Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO2TECT conversion study of vadadustat versus darbepoetin alfa in non-dialysis-dependent chronic kidney disease anemia
MOH_2018-12-05_004829Phase 3Active, not recruiting
- Sponsor
- Akebia Therapeutics
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat in Uraemic Anaemia (2 arms), sponsored by Akebia Therapeutics. Primary endpoint: Primary endpoint not reported in registry entry. Started May 2016; status: active, not recruiting.
02
Drugs
vadadustat
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on MOH_2018-12-05_004829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-05_004829.